Ling, S.W.; de Blois, E.; Hooijman, E.; van der Veldt, A.; Brabander, T.
Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics 2022, 14, 2166.
https://doi.org/10.3390/pharmaceutics14102166
AMA Style
Ling SW, de Blois E, Hooijman E, van der Veldt A, Brabander T.
Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 2022; 14(10):2166.
https://doi.org/10.3390/pharmaceutics14102166
Chicago/Turabian Style
Ling, Sui Wai, Erik de Blois, Eline Hooijman, Astrid van der Veldt, and Tessa Brabander.
2022. "Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer" Pharmaceutics 14, no. 10: 2166.
https://doi.org/10.3390/pharmaceutics14102166
APA Style
Ling, S. W., de Blois, E., Hooijman, E., van der Veldt, A., & Brabander, T.
(2022). Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics, 14(10), 2166.
https://doi.org/10.3390/pharmaceutics14102166